Galderma Group AGXSWX:GALD -0.89%15 Forward PE Ratio is 47.33 as of Jul. 11, 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 409 Drug Manufacturers companies, Galderma Group AG ranks worse than 86.8% on this metric.
Galderma Group AG (XSWX:GALD) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Galderma Group AG Forward PE Ratio Related Terms
Galderma Group AG Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG Forward PE Ratio Chart
Galderma Group AG Annual Data
Trend
2025-12
Forward PE Ratio
45.98
Galderma Group AG Semi-Annual Data
2025-06
2025-12
Forward PE Ratio
53.45
45.98
XSWX:GALD vs ZTS, UTHR, VTRS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Galderma Group AG (XSWX:GALD) has a Forward PE Ratio of 47.33 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Galderma Group AG and its competitors. According to the industry distribution chart, Galderma Group AG ranks #355 out of 409 companies in the Drug Manufacturers industry, placing it in the top 86.8%.
Is Galderma Group AG's Forward PE Ratio too high?
Galderma Group AG's current Forward PE Ratio is 47.33. The Drug Manufacturers industry median Forward PE Ratio is 17.36. Galderma Group AG's value of 47.33 is 172.6% above this industry median. Based on the distribution chart, Galderma Group AG ranks #355 out of 409 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #355 out of 409 companies for Forward PE Ratio. This places Galderma Group AG in the lower half of its industry. The industry median Forward PE Ratio is 17.36. Galderma Group AG's value of 47.33 is 172.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.36, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Forward PE Ratio of 47.33 is 172.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Forward PE Ratio is 47.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Forward PE Ratio of 47.33. The current Forward PE Ratio is 47.33 and 172.6% above the Drug Manufacturers industry median of 17.36. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Forward PE Ratio is 47.33 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 